Dianne M. Perez, PhD
Lerner Research Institute,
9500 Euclid Avenue, Cleveland, Ohio 44195
Phone: (216) 444-2058
Fax: (216) 445-8204
Our main focus is to discern the roles of three α1-adrenergic receptor subtypes (α1A,α1Bandα1D) in physiological and pathophysiological states. All three subtypes are highly homologous in both structure and function, yet evidence suggests that each subtype may play unique roles in signaling and disease states. Our approaches are multi-faceted and multi-disciplined, involving transgenic and knockout mice. Our transgenic mouse models of the α1B subtype develop cardiac hypertrophy, hypotension, and neurodegeneration. However, the α1A subtype appears to be cardioprotective and neuroprotective. Transgenic mice of the α1A subtype protect against ischemic damage in the heart and can precondition against further damage. In the brain, the α1A subtype is anti-epileptic, increases cognitive functions and is involved in neurogenesis. Administration of anα1Aagonist in the drinking water of normal mice increased learning and memory, in addition to increasing neurogenesis. Our work suggests that α1A agonists may offer new therapeutic treatments for cognitive decline, neurodegeneration and myocardial infarction.
Our body′s “fight or flight” response is regulated through a chemical called adrenaline released through nerve endings. Adrenaline works by attaching to proteins called receptors that are placed in essentially every organ and tissue throughout the body. How one drug can regulate all the organs in the body at the same time and do so in variant ways is through different adrenergic receptors called subtypes. I work on different adrenergic receptor subtypes and can demonstrate how one subtype can protect the heart against damage from heart attacks or can increase your ability to remember things by growing new neurons in the brain.
- Shi T, Papay RS and Perez DM. The role of α1-adrenergic receptors in regulating metabolism: Increased glucose tolerance, leptin secretion, and lipid oxidation. J Receptors Signal Transduction (in press).
- Shi T, Papay RS and Perez DM. α1A-Adrenergic receptor prevents cardiac ischemic damage through PKCδ/GLUT1/4-mediated glucose uptake. J Receptors Signal Transduction, 36(3):261-70, 2016.
- Collette KM, Zhou XD, Amoth HM, Lyons MJ, Papay RS, Sens DA, Perez DM, Doze VA. Long-term α1B-adrenergic receptor activation shortens lifespan while α1A-adrenergic receptor stimulation prolongs lifespan in association with decreased cancer incidence. Age, 36:9675-7, 2014. PMCID: PMC24994537
- Papay RS, Shi T, Piascik MT, Naga Prasad SV and Perez DM. α1A-Adrenergic Receptors regulate cardiac hypertrophy In Vivo through IL-6 secretion. Molecular Pharmacology 83: 939-948, 2013. PMCID: PMC3629827
- Shi T, Moravec CS and Perez DM. Novel proteins associated with human dilated cardiomyopathy: Selective reduction in α1A-adrenergic receptors and increased desensitization proteins. J Receptors Signal Transduction 33: 96-106, 2013. PMCID: PMC3624731
- Shi T, Papay RS & Perez DM. α1A-AR differentially regulates STAT3 phosphorylation through PKCε and PKCδ in myocytes. J Recept Signal Transduct Res 32:76, 2012.
- Doze VA & Perez DM. G-Protein Coupled Receptors in Adult Neurogenesis. Pharm Rev 64:645, 2012.
- Doze VA, Papay RS...Perez DM. Long term α1A-adrenergic receptor stimulation improves synaptic plasticity, cognitive function, mood and longevity. Mol Pharmacol 80:747, 2011.
- Perez DM & Doze VA. Cardiac and Neuroprotection Regulated by α1-Adrenergic Receptor Subtypes. J Recept Signal Transduct Res 31:98, 2011.
- Perez DM, Papay RS, & Shi T. α1-Adrenergic Receptor Stimulates IL-6 Expression and Secretion through both mRNA Stability & Transcriptional Regulation: Involvement of p38 MAPK and NF-kB. Mol Pharmacol 76:144, 2009.
- Gupta MK, Papay RS, Jurgens CW, Gaivin RJ, Shi T, Doze VA, Perez DM. α1-Adrenergic Receptors Regulate Neurogenesis & Gliogenesis. Mol Pharmacol 76:314, 2009.
Promising Alzheimer’s Therapeutic Secures Significant Dollars and Support from NIH for Next Phase of Study
The National Institute on Aging (NIA), part of the National Institutes of Health, has awarded Dianne Perez, PhD, a five-year, $2 million grant to continue her work to develop a novel treatment for Alzheimer’s disease.
Dianne Perez, PhD, Staff, Department of Molecular Cardiology, has been named the Alzheimer's Drug Discovery Foundation (ADDF)-Harrington Scholar for her promising research in Alzheimer's disease (AD). The award provides up to $600,000 in project funding over the course of two years, which she will use to evaluate the cognitive effects of a drug she has spent nearly 30 years researching and developing.